areas with metaplasia. In addition, prostate of PvþHg-De animals suffered loss of epithelial conformation and alveolar limitation in relation to stroma. Angiogenesis and infiltration of immune system cells were observed throughout the prostate tissue. However, nerve transection did not significantly affect the expression of the measured receptors.
INTRODUCTION AND OBJECTIVES:
Metastasis is a complex cascade that involves both intravasation of tumor cells into systemic circulation and extravasation into the target metastatic site. Although visualizing tumor cell motility in vivo has been established, the underlying mechanisms of tumor cell metastasis remain largely unknown. In this study, we developed an in vitro model for recapitulating an in vivo microenvironment to observe prostate carcinoma cell metastasis.
METHODS: To allow for high resolution and real-time imaging of tumor intravasation, we developed a micro-metastatic model by constructing a microfluidic polydimethylsiloxane (PDMS) device to mimic a primary tumor site and a metastatic site with an interconnecting vascular-type loop in three-dimensions. We also developed a macromodel device for creating a primary tumor site and metastatic sites. The primary tumor and metastatic sites were connected with vessel-mimicking tubing which was coated with type I collagen. Cell culture media was circulated between the primary and metastatic sites using a peristaltic pump. Prostate carcinoma cells (PC3/luc) were labeled with Cell Trackerâ and seeded into primary tumor site containing biomimetic collagen extracellular matrix within a microfluidic device or 6-well tissue culture plate. Bone stromal cells (HS-5) were seeded into metastatic microenvironment site.
RESULTS: We observed in both devices intravasation and circulation of the tumor cells using fluorescent microscope and plate reader. In addition, we found tumor cells at the metastatic site in the macromodel.
CONCLUSIONS: In summary, we have developed several model systems that mimic key steps of the metastatic cascade including intravasation and the accompanying presence of circulating tumor cells, followed by extravasation and the accompanying presence of disseminated tumor cells. Such systems will allow both exploration of mechanisms of metastasis and development of novel biologic assays for discovery of new therapeutics.
Source of Funding: None

MP70-07 IDENTIFYING OF PROSTATE CANCER CELL-SPECIFIC INTERNALIZING APTAMERS AND ENGINEERING OF APTAMER-TARGETED NANOPARTICLES FOR PROSTATE CANCER THERAPY
Changwei Ji*, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: To isolate cell-specific internalizing aptamers (Apt) against prostate cancer cells and evaluating their efficiency in vitro and in vivo. Engineering aptamer-targeted nanoparticles for prostate cancer therapy.
METHODS: Cell-uptake selection: Incubating prostate normal cells in the 2'-OMe-RNA pools (counter-selection), washing and collecting the unbound RNAs and presenting them to PCa cells for cellspecific binding and uptaking. Extracting the RNAs which bind to PCa cells (cell-uptake selection) and amplifying them via rtPCR. The rtPCR products were then transcribed into 2'-OMe-RNAs for the next round of selection and sequenced for Apt indentification in the last round selection. Encapsulating docetaxel (Dtxl) in Apt-targeted NPs (PLGA-PEG-Apt-Dtxl) via single emulsion method. The drug loading efficacy and payload releasing profile of the NPs were analysised in vitro. PC3 cells were planted subcutaneously on SCID mice to establish the prostate cancer model. PLGA-PEG-Apt-Dtxl were applied to the SCID mouse to evaluate the therapy efficiency of the Apt-targeted NPs.
RESULTS: Three Apts were isolated through cell-uptake selection: XEO2 and XEO9 can specificly bind to PC3 cells, and XEO6 can specificly bind to LNCaP cells. XEO2 was further trunked and modified into XEO2 mini, which with a smaller size (32 bp) and keep the targeting properties. The size of PLGA-PEG-Apt NPs was around 180 nm and the zeta potential is around -20 mV. The Dtxl loading efficacy of PLGA-PEG nanoparticles was 14.76% and the drug loading efficiency can be up to 73.8%. In vitro and in vivo experiments demonstrated that XEO2 mini targeted NPs can specificly bind to PC3 cells and better therapy efficiency was observed in SCID mice PCa models in compare with non targeted NPs or Dtxl only (Figure 1) .
CONCLUSIONS: A group of Apts which can specifically target to PCa cells have been generated by a simple cell-uptake selection progress. Cell-uptake selection can be done without prior knowledge of target molecules and can be applied in a wide variety of onlogic diseases. A PLGA-PEG-Apt-Dtxl targeted NP platform has been developed and demonstrated enhanced therapeutic efficacy in prostate cancer.
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